Vanguard Global Advisers
ALNY icon

Vanguard Global Advisers’s Alnylam Pharmaceuticals ALNY Stock Holding History

Vanguard Global Advisers’s Portfolio ALNY Stock Details ALNY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$19.3M Sell
64,254
-1,136
-2% -$343K 0.01% 570
2026
Q1 		$21.6M Buy
+65,390
New +$22.3M 0.01% 547

Other funds holding ALNY

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Vanguard Global Advisers's ALNY Position: Q2 2026 in Review

Vanguard Global Advisers reduced its Alnylam Pharmaceuticals (ALNY) stake by 1.7% in Q2 2026, selling an estimated $343K and leaving 64,254 shares worth $19.3M. The position accounts for 0.01% of the portfolio, ranked #570.

Vanguard Global Advisers first reported a position in ALNY in Q1 2026 and has held it in 2 quarters since. The position peaked at $21.6M in Q1 2026. 733 funds tracked by Wall St. Rank hold ALNY as of Q2 2026.

  • Vanguard Global Advisers held 64,254 shares of Alnylam Pharmaceuticals worth $19.3M as of Q2 2026.
  • Vanguard Global Advisers sold 1,136 Alnylam Pharmaceuticals shares in Q2 2026, an estimated $343K.
  • Alnylam Pharmaceuticals made up 0.01% of Vanguard Global Advisers's portfolio in Q2 2026, its #570 holding.
  • Vanguard Global Advisers first reported a position in Alnylam Pharmaceuticals in Q1 2026 and has held it in 2 quarters since.
  • Vanguard Global Advisers's Alnylam Pharmaceuticals position peaked at $21.6M in Q1 2026.
  • 733 funds tracked by Wall St. Rank held Alnylam Pharmaceuticals as of Q2 2026.

Based on Vanguard Global Advisers's 13F filing for Q2 2026, filed 13 Aug 2026.